Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-08 3:04 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 575,892 5.100% | 575,892 (New Position) | Filing History |
| 2024-11-27 11:01 am Purchase | 2024-11-20 | 13G | Savara Inc. SVRA | Frazier Life Sciences Public Fund, L.P. | 8,660,379 5.000% | 8,660,379 (New Position) | Filing History |
| 2024-11-20 10:44 am Purchase | 2024-11-14 | 13G | MacroGenics, Inc. MGNX | Frazier Life Sciences Public Fund, L.P. | 3,175,665 5.100% | 3,175,665 (New Position) | Filing History |
| 2024-11-07 2:34 pm Purchase | 2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% | 1,200,000 (+32.54%) | Filing History |
| 2024-11-06 10:30 am Purchase | 2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 7,381,090 10.200% | 717,500 (+10.77%) | Filing History |
| 2024-11-05 11:44 am Purchase | 2024-10-30 | 13G | Eledon Pharmaceuticals, Inc. ELDN | Frazier Life Sciences Public Fund, L.P. | 3,561,644 6.100% | 3,561,644 (New Position) | Filing History |
| 2024-09-23 10:48 am Purchase | 2024-09-16 | 13D | MBX Biosciences, Inc. Common Stock MBX | Frazier Life Sciences Public Fund, L.P. | 5,985,347 18.800% | 5,985,347 (New Position) | Filing History |
| 2024-08-22 4:05 pm Purchase | 2024-08-20 | 13D | Phathom Pharmaceuticals, Inc. PHAT | Frazier Life Sciences Public Fund, L.P. | 12,788,710 18.000% | 2,618,922 (+25.75%) | Filing History |
| 2024-07-15 1:17 pm Purchase | 2024-07-11 | 13G | Elevation Oncology, Inc. ELEV | Frazier Life Sciences Public Fund, L.P. | 5,993,579 11.000% | 3,035,000 (+102.58%) | Filing History |
| 2024-06-25 10:06 am Purchase | 2024-06-17 | 13G | Disc Medicine, Inc. IRON | Frazier Life Sciences Public Fund, L.P. | 1,754,834 5.900% | 1,754,834 (New Position) | Filing History |
| 2024-06-06 1:59 pm Purchase | 2024-03-07 | 13D | Phathom Pharmaceuticals, Inc. PHAT | Frazier Life Sciences Public Fund, L.P. | 10,169,788 17.400% | 44,000 (+0.43%) | Filing History |
| 2024-05-31 2:00 pm Purchase | 2024-05-29 | 13D | HilleVax, Inc. HLVX | Frazier Life Sciences Public Fund, L.P. | 10,639,562 21.400% | 833,090 (+8.50%) | Filing History |
| 2024-05-29 11:55 am Purchase | 2024-05-21 | 13G | Erasca, Inc. ERAS | Frazier Life Sciences Public Fund, L.P. | 16,216,216 5.900% | 16,216,216 (New Position) | Filing History |
| 2024-05-06 12:59 pm Purchase | 2024-04-29 | 13G | AnaptysBio, Inc. ANAB | Frazier Life Sciences Public Fund, L.P. | 1,917,191 7.000% | 1,917,191 (New Position) | Filing History |
| 2024-04-10 4:44 pm Purchase | 2024-04-03 | 13G | AN2 Therapeutics, Inc. ANTX | Frazier Life Sciences Public Fund, L.P. | 1,488,889 5.000% | 1,488,889 (New Position) | Filing History |
| 2024-04-09 4:26 pm Purchase | 2024-04-02 | 13G | Elevation Oncology, Inc. ELEV | Frazier Life Sciences Public Fund, L.P. | 2,958,579 6.100% | 2,958,579 (New Position) | Filing History |
| 2024-03-29 10:40 am Purchase | 2024-03-25 | 13G | Puma Biotechnology, Inc. PBYI | Frazier Life Sciences Public Fund, L.P. | 2,631,713 5.400% | 2,631,713 (New Position) | Filing History |
| 2024-02-22 1:22 pm Purchase | 2024-02-20 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 3,687,867 8.900% | 105,573 (+2.95%) | Filing History |
| 2024-02-13 12:44 pm Sale | 2023-12-31 | 13G | GRITSTONE BIO INC GRTSQ | Frazier Life Sciences Public Fund, L.P. | 1,092,185 1.100% | -4,131,470 (-79.09%) | Filing History |
| 2024-02-13 12:36 pm Sale | 2023-12-31 | 13G | Theseus Pharmaceuticals, Inc. THRX | Frazier Life Sciences Public Fund, L.P. | 0 0.000% | -2,248,194 (Position Closed) | Filing History |